TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors

References

• Ahn Y, Oh S, Lee SJ, et al. (2014). Synthesis of diethylamino-curcumin mimics with substituted triazolyl groups and their sensitization effect of TRAIL against brain cancer cells. Bioorg Med Chem Lett 24:3346–50.
   PubMed Web of Science ®Google Scholar
• An D, Kim K, Kim J. (2014). Microfluidic system based high throughput drug screening system for curcumin/TRAIL combinational chemotherapy in human prostate cancer PC3 cells. Biomol Ther (Seoul) 22:355–62.
   PubMed Web of Science ®Google Scholar
• Anand P, Sundaram C, Jhurani S, et al. (2008). Curcumin and cancer: an “old-age disease with an age-old solution”. Cancer Lett 267:133–64.
   PubMed Web of Science ®Google Scholar
• Andrzejewski T, Deeb D, Gao X, et al. (2008). Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol Res 17:257–67.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420–30.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Holland P, Eckhardt SG. (2008). Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). JCO 26:3621–30.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–62.
   PubMed Web of Science ®Google Scholar
• Bellail AC, Tse MC, Song JH, et al. (2010). DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med 14:1303–17.
   PubMed Web of Science ®Google Scholar
• Bouralexis S, Clayer M, Atkins GJ, et al. (2004). Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin. Int J Oncol 24:1263–70.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. (2016). Cancer statistics in China, 2015. CA Cancer J Clin 66:115–32.
   PubMed Web of Science ®Google Scholar
• De Miguel D, Gallego-Lleyda A, Ayuso JM, et al. (2016a). TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells. Nanotechnology 27:185101.
   PubMed Web of Science ®Google Scholar
• De Miguel D, Gallego-Lleyda A, Ayuso JM, et al. (2016b). High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. Cancer Lett 383:250–60.
   PubMed Web of Science ®Google Scholar
• Deeb D, Jiang H, Gao X, et al. (2007). Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J Pharmacol Exp Ther 321:616–25.
   PubMed Web of Science ®Google Scholar
• Egan ME, Pearson M, Weiner SA, et al. (2004). Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304:600–2.
   PubMed Web of Science ®Google Scholar
• Evdokiou A, Bouralexis S, Atkins GJ, et al. (2002). Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99:491–504.
   PubMed Web of Science ®Google Scholar
• Gou M, Zheng L, Peng X, et al. (2009a). Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm 375:170–6.
   PubMed Web of Science ®Google Scholar
• Gou M, Zheng X, Men K, et al. (2009b). Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. J Phys Chem B 113:12928–33.
   PubMed Web of Science ®Google Scholar
• Guo L, Fan L, Ren J, et al. (2011). A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes. Nanotechnology 22:265105.
   PubMed Web of Science ®Google Scholar
• Guo L, Fan L, Ren J, et al. (2012). Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine 7:1449–60.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, et al. (2010). Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. JCO 28:2839–46.
   PubMed Web of Science ®Google Scholar
• James MA, Seibel WL, Kupert E, et al. (2015). A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression. Anticancer Drugs 26:518–30.
   PubMed Web of Science ®Google Scholar
• Jiang HH, Kim TH, Lee S, et al. (2011). PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 32:8529–37.
   PubMed Web of Science ®Google Scholar
• Jung EM, Lim JH, Lee TJ, et al. (2005). Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26:1905–13.
   PubMed Web of Science ®Google Scholar
• Jung EM, Park JW, Choi KS, et al. (2006). Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis 27:2008–17.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Tharakan ST, Sung B, Aggarwal BB. (2009). Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 69:8958–66.
   PubMed Web of Science ®Google Scholar
• Kim I, Byeon HJ, Kim TH, et al. (2013). Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials 34:6444–53.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, Storm G. (2012). Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161:175–87.
   PubMed Web of Science ®Google Scholar
• Lee AL, Dhillon SH, Wang Y, et al. (2011). Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Mol Biosyst 7:1512–22.
   PubMed Web of Science ®Google Scholar
• Munshi A, Mcdonnell TJ, Meyn RE. (2002). Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 50:46–52.
   PubMed Web of Science ®Google Scholar
• Naka T, Sugamura K, Hylander BL, et al. (2002). Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62:5800–6.
   PubMed Web of Science ®Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. (2014). Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 35:3365–83.
   PubMed Web of Science ®Google Scholar
• Pan LQ, Wang HB, Xie ZM, et al. (2013). Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery. Adv Mater 25:4718–22.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–60.
   PubMed Web of Science ®Google Scholar
• Photos PJ, Bacakova L, Discher B, et al. (2003). Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 90:323–34.
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Chiodoni C, Squarcina P, et al. (2016). TNF-related apoptosis-inducing ligand (TRAIL)-armed exosomes deliver proapoptotic signals to tumor site. Clin Cancer Res 22:3499–512.
   PubMed Web of Science ®Google Scholar
• Shi C, Guo X, Qu Q, et al. (2014). Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles. Biomaterials 35:8711–22.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer Statistics, 2017. CA Cancer J Clin 67:7–30.
   PubMed Web of Science ®Google Scholar
• Singh TR, Shankar S, Chen X, et al. (2003). Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63:5390–400.
   PubMed Web of Science ®Google Scholar
• Torchilin V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–5.
   PubMed Web of Science ®Google Scholar
• Wei X, Gong C, Shi S, et al. (2009). Self-assembled honokiol-loaded micelles based on poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymer. Int J Pharm 369:170–5.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–82.
   PubMed Web of Science ®Google Scholar
• Xu L, Hu X, Qu X, et al. (2013). Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts. Biochem Biophys Res Commun 439:285–90.
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Shiraki K, Sugimoto K, et al. (2000). Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32:482–90.
   PubMed Web of Science ®Google Scholar
• Yang CL, Ma YG, Xue YX, et al. (2012). Curcumin induces small cell lung cancer NCI-H446 cell apoptosis via the reactive oxygen species-mediated mitochondrial pathway and not the cell death receptor pathway. DNA Cell Biol 31:139–50.
   PubMed Web of Science ®Google Scholar
• Yang X, Li Z, Wang N, et al. (2015). Curcumin-encapsulated polymeric micelles suppress the development of colon cancer in vitro and in vivo. Sci Rep 5:10322.
   PubMed Web of Science ®Google Scholar
• Zhang L, He Y, Ma G, et al. (2012). Paclitaxel-loaded polymeric micelles based on poly(varepsilon-caprolactone)-poly(ethylene glycol)-poly(varepsilon-caprolactone) triblock copolymers: in vitro and in vivo evaluation. Nanomedicine 8:925–34.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wientjes MG, Au JL. (2004). Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram and combination index analyses. Clin Cancer Res 10:7994–8004.
   PubMed Web of Science ®Google Scholar